Detalhe da pesquisa
1.
Tumor circadian clock strength influences metastatic potential and predicts patient prognosis in luminal A breast cancer.
Proc Natl Acad Sci U S A
; 121(7): e2311854121, 2024 Feb 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38319971
2.
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.
N Engl J Med
; 388(22): 2058-2070, 2023 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37256976
3.
Pathogenic variant detection rate varies considerably in male breast cancer families and sporadic cases: minimal additional contribution beyond BRCA2, BRCA1 and CHEK2.
J Med Genet
; 2024 Apr 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38609177
4.
Germline testing of BRCA1, BRCA2, PALB2 and CHEK2 c.1100delC in 1514 triple negative familial and isolated breast cancers from a single centre, with extended testing of ATM, RAD51C and RAD51D in over 400.
J Med Genet
; 61(4): 385-391, 2024 Mar 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38123987
5.
A novel preclinical model of the normal human breast.
J Mammary Gland Biol Neoplasia
; 29(1): 9, 2024 May 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38695983
6.
Detection of pathogenic variants in breast cancer susceptibility genes in bilateral breast cancer.
J Med Genet
; 60(10): 974-979, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37055167
7.
Differential involvement of germline pathogenic variants in breast cancer genes between DCIS and low-grade invasive cancers.
J Med Genet
; 60(8): 740-746, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36442995
8.
Quantifying the effects of risk-stratified breast cancer screening when delivered in real time as routine practice versus usual screening: the BC-Predict non-randomised controlled study (NCT04359420).
Br J Cancer
; 128(11): 2063-2071, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37005486
9.
CDK4/6 inhibitors versus weekly paclitaxel for treatment of ER+/HER2- advanced breast cancer with impending or established visceral crisis.
Breast Cancer Res Treat
; 202(1): 83-95, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37584881
10.
Breast cancer polygenic risk scores derived in White European populations are not calibrated for women of Ashkenazi Jewish descent.
Genet Med
; 25(9): 100846, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37061873
11.
"I don't know what I'm feeling for": young women's beliefs about breast cancer risk and experiences of breast awareness.
BMC Womens Health
; 23(1): 312, 2023 06 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-37328760
12.
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial.
Lancet Oncol
; 23(7): 851-864, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35671774
13.
The importance of ethnicity: Are breast cancer polygenic risk scores ready for women who are not of White European origin?
Int J Cancer
; 150(1): 73-79, 2022 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34460111
14.
Randomised controlled trial of intermittent vs continuous energy restriction during chemotherapy for early breast cancer.
Br J Cancer
; 126(8): 1157-1167, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34912072
15.
Breast cancer risk stratification in women of screening age: Incremental effects of adding mammographic density, polygenic risk, and a gene panel.
Genet Med
; 24(7): 1485-1494, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35426792
16.
Breast cancer incidence and early diagnosis in a family history risk and prevention clinic: 33-year experience in 14,311 women.
Breast Cancer Res Treat
; 189(3): 677-687, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34312777
17.
Clinical utility of testing for PALB2 and CHEK2 c.1100delC in breast and ovarian cancer.
Genet Med
; 23(10): 1969-1976, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34113003
18.
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial.
Lancet Oncol
; 21(3): 345-357, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32035020
19.
Carboplatin dose capping affects pCR rate in HER2-positive breast cancer patients treated with neoadjuvant Docetaxel, Carboplatin, Trastuzumab, Pertuzumab (TCHP).
Breast Cancer Res Treat
; 184(2): 481-489, 2020 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-32860550
20.
Correction: Breast cancer in neurofibromatosis 1: survival and risk of contralateral breast cancer in a five country cohort study.
Genet Med
; 22(1): 242, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31591510